COCP News & Events

Cocrystal Pharma has appointed James Sapirstein CEO, effective immediately. The company also plans to appoint Sapirstein as a member of the board of directors. Sapirstein replaces Sam Lee and Jim Martin, who served as co-CEOs. Sam Lee will continue as president and transition to chief scientific officer, and Jim Martin will continue as CFO. Sapirstein was CEO of Contravir Pharmaceuticals.

Cocrystal Pharma files $150M mixed securities shelf

Cocrystal Pharma announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.